GPC3-CAR-T cell therapy(Origincell Medical Technology)

靶向GPC3嵌合抗原受体自体T细胞(原启生物)

Report date: 2026/05/21 20:00:22

Base Information

Drug NameGPC3-CAR-T cell therapy(Origincell Medical Technology)
Drug Alias NameOri-CAR-001Ori-C101（OriCell）GPC3-CAR-ori2 cellG3-CAR-ori2 cellG3-CAR-ori2
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionGlypican-3 modulatorsGene transferenceWnt signalling pathway inhibitors
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesOriCell Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesOriCell Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A